On March 17, 2022, the Board of Directors (the Board) of Emergent BioSolutions Inc. (the Company) appointed Keith Katkin as a Class I director of the Company, effective as of April 1, 2022 (the Effective Date), with an initial term expiring at the 2022 annual meeting of stockholders. He was also appointed as a member of both the Nominating and Corporate Governance Committee and Strategic Operations Committee of the Board, as of the Effective Date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.72 USD | -0.84% | -8.88% | +96.67% |
May. 02 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
May. 02 | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+96.67% | 247M | |
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+13.62% | 238B | |
+6.99% | 204B | |
-6.46% | 203B | |
+4.23% | 161B | |
-1.70% | 160B |
- Stock Market
- Equities
- EBS Stock
- News Emergent BioSolutions Inc.
- Emergent BioSolutions Inc. Appoints Keith Katkin as a Class I Director, Member of Both the Nominating and Corporate Governance Committee and Strategic Operations Committee of the Board